The
effort to find an effective analgesic with less
dependence-producing consequences led to the development
of pentazocine (Talwin®). Introduced as an
analgesic in 1967, it was frequently encountered
in the illicit trade, usually in combination with
tripelennamine and placed into Schedule IV of
the CSA in 1979. An attempt at reducing the abuse
of this drug was made with the introduction of
Talwin Nx®. This product contains a quantity
of antagonist (naloxone) sufficient to counteract
the morphine-like effects of pentazocine if the
tablets are dissolved and injected.
Source: DEA
|
